Skip to main content
Publications
Danysh HE , Gilsenan A , Kaye JA, Garcia de Albeniz Martinez X , Schmid R, Bartsch J , Calingaert B , Rahman S, Layton JB , Gutierrez L . Validation of algorithms to identify breast cancer and bladder cancer among patients with type 2 diabetes mellitus in United States medicare administrative claims . Poster presented at the 2024 ISPE Annual Meeting; August 28, 2024. Berlin, Germany.
Stattin P, Westerberg M, Franck Lissbrant I, Hjalm-Eriksson M, Kjellman A, Ullen A, Vassilev Z, Sandstrom P, Weinrib R , Martinez D , Garcia de Albeniz Martinez X . Real world outcomes in patients with metastatic, castration-resistant prostate cancer treated with radium-223 in routine clinical practice in Sweden . Clin Genitourin Cancer. 2022 Sep 9;S1558-7673(22):00194-X. doi: 10.1016/j.clgc.2022.09.002
Danysh HE , Gilsenan A , Beachler DC, Kaye JA, Garcia-Albeniz X , Schmid R, Hunter S, Hunt PR, Aguado J , Calingaert B , Layton JB , Gutierrez L . Validation of breast cancer and bladder cancer among patients with type 2 diabetes mellitus in Medicare: a pilot study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Garcia de Albeniz X , Riera Guardia N , Gutierrez L , Bahmanyar S, Blin P, Droz C, Heinig M, Linder M, Moore N, Schulze-Rath R, Sultana J, Trifiro G, Zhang WW, Zong J. Feasibility of studying the use of tissue-agnostic cancer drugs in population-based European health databases . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.
Garcia-Albeniz X , Alonso V, Escudero P, Méndez M, Gallego J, Rodríguez JR, Salud A, Fernández-Plana J, Manzano H, Zanui M, Falcó E, Feliu J, Gil M, Fernández-Martos C, Bohn U, Alonso C, Calderero V, Rojo F, Cuatrecasas M, Maurel J. Prospective biomarker study in advanced RAS wild‐type colorectal cancer: POSIBA Trial (GEMCAD 10‐02) . Oncologist. 2019 Nov;24(11):e1115-22. doi: 10.1634/theoncologist.2018-0728
Osorio J, Jerico C, Miranda C, Garsot E, Luna A, Miro M, Santamaria M, Artigau E, Rodriguez-Santiago J, Castro S, Feliu J, Aldeano A, Olona C, Momblan D, Ruiz D, Galofre G, Pros I, Garcia-Albeniz X , Lozano M, Pera M. Perioperative transfusion management in gastric cancer surgery: analysis of the Spanish subset of the EURECCA oesophago-gastric cancer registry . Cir Esp. 2018 Nov;96(9):546-54. doi: 10.1016/j.ciresp.2018.03.010
Alonso V, Escudero P, Fernandez-Martos C, Salud A, Mendez M, Gallego J, Rodriguez JR, Martin-Richard M, Fernandez-Plana J, Manzano H, Mendez JC, Zanui M, Falco E, Gil-Raga M, Rojo F, Cuatrecasas M, Feliu J, Garcia-Albeniz X , Maurel J. Coexpression of p-IGF-1R and MMP-7 modulates panitumumab and cetuximab efficacy in RAS wild-type metastatic colorectal cancer patients . Neoplasia. 2018 Jul;20(7):678-86. doi: 10.1016/j.neo.2018.05.004
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X . Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial . Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.
Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martinez-Cardus A, Marin-Aguilera M, Horndler C, Martinez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martin-Richard M, Alonso V, Escudero P, Fernandez-Martos C, Feliu J, Mendez JC, Mendez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, Garcia-Albeniz X , Camps J, Maurel J. Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer . Br J Cancer. 2017 Dec 5;117(12):1777-86. doi: 10.1038/bjc.2017.279.
Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X , Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial . Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509
Caballero-Banos M, Benitez-Ribas D, Tabera J, Varea S, Vilana R, Bianchi L, Ayuso JR, Pages M, Carrera G, Cuatrecasas M, Martin-Richard M, Cid J, Lozano M, Castells A, Garcia-Albeniz X , Maurel J, Vilella R. Phase II randomised trial of autologous tumour lysate dendritic cell plus best supportive care compared with best supportive care in pre-treated advanced colorectal cancer patients . Eur J Cancer. 2016 Sep;64:167-74. doi: 10.1016/j.ejca.2016.06.008
Maurel J, Fernandez-Martos C, Martin-Richard M, Alonso V, Mendez JC, Salud A, Pericay C, Aparicio J, Gallego J, Carmona A, Casado E, Manzano H, Horndler C, Rubini M, Cuatrecasas M, Garcia-Albeniz X , Feliu J. Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)] . Poster presented at the 2016 ASCO Annual Meeting; January 23, 2016. Chicago, IL. [abstract] J Clin Oncol. 2016 Feb; 34(4_Suppl):583. doi: 10.1200/jco.2016.34.4_suppl.583
Garcia-Albeniz X , Rudolph A, Hutter C, White E, Lin Y, Rosse SA, Figueiredo JC, Harrison TA, Jiao S, Brenner H, Casey G, Hudson TJ, Thornquist M, Le Marchand L, Potter J, Slattery ML, Zanke B, Baron JA, Caan BJ, Chanock SJ, Berndt SI, Stelling D, Fuchs CS, Hoffmeister M, Butterbach K, Du M, James Gauderman W, Gunter MJ, Lemire M, Ogino S, Lin J, Hayes RB, Haile RW, Schoen RE, Warnick GS, Jenkins MA, Thibodeau SN, Schumacher FR, Lindor NM, Kolonel LN, Hopper JL, Gong J, Seminara D, Pflugeisen BM, Ulrich CM, Qu C, Duggan D, Cotterchio M, Campbell PT, Carlson CS, Newcomb PA, Giovannucci E, Hsu L, Chan AT, Peters U, Chang-Claude J. CYP24A1 variant modifies the association between use of oestrogen plus progestogen therapy and colorectal cancer risk . Br J Cancer. 2016 Jan 19;114(2):221-9. doi: 10.1038/bjc.2015.443
Pavlovic M, Arnal-Estape A, Rojo F, Bellmunt A, Tarragona M, Guiu M, Planet E, Garcia-Albeniz X , Morales M, Urosevic J, Gawrzak S, Rovira A, Prat A, Nonell L, Lluch A, Jean-Mairet J, Coleman R, Albanell J, Gomis RR. Enhanced MAF oncogene expression and breast cancer bone metastasis . J Natl Cancer Inst. 2015 Sep 15;107(12):djv256. doi: 10.1093/jnci/djv256
Fernandez-Martos C, Garcia-Albeniz X , Pericay C, Maurel J, Aparicio J, Montagut C, Safont MJ, Salud A, Vera R, Massuti B, Escudero P, Alonso V, Bosch C, Martin M, Minsky BD. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial . Ann Oncol. 2015 Aug;26(8):1722-8. doi: 10.1093/annonc/mdv223
Garcia-Albeniz X , Gallego R, Hofheinz RD, Fernandez-Esparrach G, Ayuso-Colella JR, Bombí JA, Conill C, Cuatrecasas M, Delgado S, Gines A, Miquel R, Pages M, Pineda E, Pereira Y, Sosa A, Reig O, Victoria I, Feliz L, María de Lacy A, Castells A, Burkholder I, Hochhaus A, Maurel J. Adjuvant therapy sparing in rectal cancer achieving complete response after chemoradiation . World J Gastroenterol. 2014 Nov 14;20(42):15820-9. doi: 10.3748/wjg.v20.i42.15820
Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, Ortego J, Gallego R, Codony-Servat J, Garcia-Albeniz X , Jares P, Castells A, Lozano JJ, Rosell R, Maurel J. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy . Eur J Cancer. 2014 Jul;50(11):1973-81. doi: 10.1016/j.ejca.2014.04.019
Urosevic J, Garcia-Albeniz X , Planet E, Real S, Cespedes MV, Guiu M, Fernandez E, Bellmunt A, Gawrzak S, Pavlovic M, Mangues R, Dolado I, Barriga FM, Nadal C, Kemeny N, Batlle E, Nebreda AR, Gomis RR. Colon cancer cells colonize the lung from established liver metastases through p38 MAPK signalling and PTHLH . Nat Cell Biol. 2014 Jul;16(7):685-94. doi: 10.1038/ncb2977
Martin-Richard M, Gallego R, Pericay C, Garcia Foncillas JG, Queralt B, Casado E, Barriuso J, Iranzo V, Juez I, Visa L, Saigi E, Barnadas A, Garcia-Albeniz X , Maurel J. Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study . Invest New Drugs. 2013 Dec;31(6):1573-9.
Garcia-Albeniz X , Rudolph A, Hutter CM, Lin Y, White E, Brenner H, Casey G, Gallinger S, Hsu L, Hudson TJ, Le Marchand L, Potter J, Slattery M, Zanke B, Newcomb PA, Chan AT, Peters U, Chang-Claude J. Genome wide gene-environment interaction study identifies a CYP24A1-related variant as a modifier of colorectal cancer risk associated with menopausal estrogen plus progesterone therapy . Presented at the 2013 American Society for Human Genetics Annual Meeting; October 24, 2013. Boston, MA.
Garcia-Albeniz X , Nan H, Valeri L, Morikawa T, Kuchiba A, Phipps AI, Hutter CM, Peters U, Newcomb PA, Fuchs CS, Giovannucci EL, Ogino S, Chan AT. Phenotypic and tumor molecular characterization of colorectal cancer in relation to a susceptibility SMAD7 variant associated with survival . Carcinogenesis. 2013 Feb;34(2):292-8. doi: 10.1093/carcin/bgs335
Phipps AI, Newcomb PA, Garcia-Albeniz X , Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. Association between colorectal cancer susceptibility loci and survival time after diagnosis with colorectal cancer . Gastroenterology. 2012 Jul;143(1):51-4. doi: 10.1053/j.gastro.2012.04.052
Alonso-Espinaco V, Marmol M, Alonso V, Escudero P, Horndler C, Ortego J, Gallego R, Garcia-Albeniz X , Jares P, Cuatrecasas M, Jose Lozano J, Castells A, Maurel J. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy . Poster presented at the 2012 ASCO Annual Meeting; June 4, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun; 30(15_Suppl):3553. doi: 10.1200/jco.2012.30.15_suppl.3553
Maurel J, Garcia-Albeniz X , Mendez Mendez C, Martin-Richard M, Pericay C, Vera R, Aparicio J, Rubini M, Cuatrecasas M. PULSE: An open-label, phase II study assessing double positivity (phospho-insulin-growth factor receptor-1 [pIGF-IR] and matrilysin [MMP7]) expression, as a predictive marker of resistance in previously untreated metastatic colorectal cancer (mCRC) wild-type KRAS patients (pts) treated with panitumumab plus mFOLFOX6—A GEMCAD study . Poster presented at the 2011 ASCO Annual Meeting; June 6, 2011. Chicago, IL. [abstract] J Clin Oncol. 2011 Jun; 29(15_suppl). doi: 10.1200/jco.2011.29.15_suppl.tps164
Carrera G, Garcia-Albeniz X , Ayuso JR, Aparicio J, Castells A, Codony-Servat J, Feliu J, Fuster D, Gallego R, Pages M, Torres F, Maurel J. Design and endpoints of clinical and translational trials in advanced colorectal cancer. a proposal from GROUP Español Multidisciplinar en Cancer Digestivo (GEMCAD) . Rev Recent Clin Trials. 2011 May;6(2):158-70. doi: 10.2174/157488711795177868
Horndler C, Gallego R, Garcia-Albeniz X , Alonso-Espinaco V, Alonso V, Escudero P, Jimeno M, Ortego J, Codony-Servat J, Fernandez-Martos C, Calatrava A, Marín-Aguilera M, Munoz J, Castellví-Bel S, Castells A, Rubini M, Gascon P, Maurel J. Co-expression of matrix metalloproteinase-7 (MMP-7) and phosphorylated insulin growth factor receptor I (pIGF-1R) correlates with poor prognosis in patients with wild-type KRAS treated with cetuximab or panitumumab: a GEMCAD study . Cancer Biol Ther. 2011 Jan 15;11(2):177-83.
Maurel J, Martins AS, Poveda A, Lopez-Guerrero JA, Cubedo R, Casado A, Martinez-Trufero J, Ramon Ayuso J, Lopez-Pousa A, Garcia-Albeniz X , Garcia del Muro X, de Alava E. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas . Cancer. 2010 Aug 1;116(15):3692-701. doi: 10.1002/cncr.25111